

28. (Amended) The antibody of claim 25, or an antigen binding fragment thereof, further comprising a pharmaceutically acceptable carrier.

30. (Amended) A recombinant anti-LFA-1 antibody, or an antigen binding fragment thereof, which selectively binds to an LFA-1 I-domain in the open conformation.

Please add new claims 76-82 as follows:

76. (New) The antibody of claim 25 or 30, or an antigen binding fragment thereof, wherein said antibody is a human antibody.

77. (New) The antibody of claim 25 or 30, or an antigen binding fragment thereof, wherein said antibody is a humanized antibody.

78. (New) The antibody of claim 25 or 30, or an antigen binding fragment thereof, wherein said antibody is a chimeric antibody.

79. (New) An antibody, or an antigen binding fragment thereof, which selectively binds to a modified I-domain of an  $\alpha$ L subunit containing amino acid substitution E284C/E301C.

80. (New) The antibody of claim 25, wherein said antibody, or antigen binding fragment thereof, is identified by screening a phage display library with a modified integrin polypeptide, and isolating said antibody, or antigen binding fragment thereof.

81. (New) The antibody of claim 79, wherein said modified integrin polypeptide is stabilized in the open conformation.

82. (New) The antibody of any one of claims 25, 30, or 79, wherein said antibody is a monoclonal antibody.